A New in Silico Antibody Similarity Measure Both Identifies Large Sets of Epitope Binders with Distinct CDRs and Accurately Predicts Off-Target Reactivity

Developing a therapeutic antibody is a long, tedious, and expensive process. Many obstacles need to be overcome, such as biophysical properties (issues of solubility, stability, weak production yields, etc.), as well as cross-reactivity and subsequent toxicity, which are major issues. No in silico m...

Descripción completa

Detalles Bibliográficos
Autores principales: Musnier, Astrid, Bourquard, Thomas, Vallet, Amandine, Mathias, Laetitia, Bruneau, Gilles, Ayoub, Mohammed Akli, Travert, Ophélie, Corde, Yannick, Gallay, Nathalie, Boulo, Thomas, Cortes, Sandra, Watier, Hervé, Crépieux, Pascale, Reiter, Eric, Poupon, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456297/
https://www.ncbi.nlm.nih.gov/pubmed/36077163
http://dx.doi.org/10.3390/ijms23179765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456297/
https://www.ncbi.nlm.nih.gov/pubmed/36077163
http://dx.doi.org/10.3390/ijms23179765

Ejemplares similares